Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shionogi To Divest Contract Manufacturer To Focus On Prescription Business

This article was originally published in PharmAsia News

Executive Summary

Osaka-based Shionogi's board of directors agreed to transfer wholly owned Bushu Pharmaceuticals to private investment fund TMC BUYOUT1, a subsidiary of Tokio Marine Capital beginning March 31. Bushu is the second-largest pharmaceutical contract manufacturer in Japan

You may also be interested in...



Shionogi Looks Beyond Crestor to HIV Platform

The company's leading HIV candidate, S-349572, is an integrase inhibitor that had the strongest efficacy ever reported for the class in a Phase IIa study.

Shionogi Looks Beyond Crestor to HIV Platform

The company's leading HIV candidate, S-349572, is an integrase inhibitor that had the strongest efficacy ever reported for the class in a Phase IIa study.

Shionogi Looks Beyond Crestor to HIV Platform

TOKYO - Shionogi still has a few years to reap the benefits of Crestor royalties from AstraZeneca, but the looming generic substitution of rival Lipitor is forcing the company to prepare for a slowdown of its blockbuster drug. But according to Macquarie Equities Research, revised ex-U.S. Crestor prospects, strong pipeline prospects and recent launches could position Shionogi well in the near term

Related Content

UsernamePublicRestriction

Register

SC074421

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel